Abstract: Modern medicine is aging with breath
taking advances in cancer care including cancer
prevention, detection, therapy, research, rehabilitation
and symptom management has seen a sea change over last
decade. In India, about 10 lakh new cancer cases are
detected every year and about same of old plus new
cancer persons die each year. The diagnosis of cancer
once confirmed by the doctor does shock the patient
beyond such a manner that one is taken aback. The
patient and family both suffer differently and that adds
to the total burden of cancer related illness. The
relationship of a doctor and oncology pharmacist carries
with the cancer patient is that of friend, philosopher
and guide telling how to add years to life and life to
years.
Latest "molecular" targeted therapy has drug categories
of two types, the "big molecule" type act on "molecules"
outside the cell membrane, as these are not able to
penetrate within cancer cell. The second "small
molecules" type act on molecules inside the cell. The
monoclonal antibodies like anti HER-2, anti CD20, anti
EGFR and anti VEGF (Herceptin@, Mabthera@, Erbitux@,
Avastin@) respectively belongs to "BIG" type whereas,
kinase inhibitors of EGFR, bcr-abl Tyrosine, EGFR (Iressa@,
Gleevac@, Tarceva@) are small types.
|
The above content is an abstract only. For the full Article please contact:
KONGPOSH Publications Pvt. Ltd.
ICS House, C-19, Commercial Complex, SDA, Opp. IIT Gate, New Delhi, India -110016
Tel.: 26855839, 20057149, Fax: 91-11-26855876
Email:
info@kppub.com /
fpc@vsnl.com, Website:
http://www.kppub.com |
